Syros Pharmaceuticals (SYRS) 10-Q2024 Q1 Quarterly report

Filed: 14 May 24, 6:42am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: affirmative, attempt, blinded, capacity, cease, chose, closure, collateral, committee, cycle, decline, description, evolution, exhibit, foreclosure, foregoing, futility, issuable, passed, Piper, preclude, recommended, renegotiate, repay, residual, Richard, Sandler, Taiho, text, unchanged, Young

Removed: accredited, acquirer, actively, addressable, adenocarcinoma, adjustment, advancement, aggregating, appoint, ascribed, ASH, assay, assumed, ATO, ATRA, authorized, began, bioavailability, breast, burden, calculate, closed, compare, composite, comprise, concept, concurrent, confirmation, consummation, convenient, converted, curative, demonstrating, designated, doubt, ductal, EMA, exercising, existence, expansion, experienced, expired, exploring, expression, extension, favorably, fiscal, force, formulation, fraction, fractional, fusion, gemcitabine, healthcare, heavily, holder, identifiable, improving, inclusive, Incorporation, Incyte, inhibitor, initiated, intravenously, intrinsic, iv, kinase, line, Listing, long, lowering, Manchester, merged, modified, monocytic, nearest, notice, opportunity, ORR, pancreatic, PDAC, pharmacokinetic, phenotype, PIPE, PK, platform, PML, potent, preceding, principally, prohibited, proportionately, put, Qiagen, RAR, recapitalization, recent, reclassified, referred, reimbursable, resistance, responsible, rounded, schedule, score, solid, split, standalone, stockholder, substantive, subtype, suggest, system, Tack, therapy, translational, typical, unexercised, validated, validation, voting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated SYRS transcripts

SYRS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Syros Pharmaceuticals, Inc. (the “Company”) for the quarter ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Conley Chee, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 14, 2024		/s/ Conley Chee
		Conley Chee
		President and Chief Executive Officer (Principal Executive Officer)